Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Valneva SE

Market Cap 434M 502M 400M 374M 701M 47.71B 712M 4.72B 1.84B 23.22B 1.88B 1.84B 80.41B P/E Ratio 2026 *
-6.23x
P/E Ratio 2027 * 6.02x
Enterprise Value 562M 650M 517M 484M 908M 61.8B 922M 6.11B 2.38B 30.08B 2.44B 2.39B 104B EV / Sales 2026 *
3.7x
EV / Sales 2027 * 1.68x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -
1 day+3.25%
1 week-2.47%
Current month-12.48%
1 month-9.64%
3 months-49.29%
6 months-38.71%
Current year-38.52%
1 week 2.18
Extreme 2.182
2.34
1 month 2.18
Extreme 2.182
2.72
Current year 2.14
Extreme 2.135
5.15
1 year 2.14
Extreme 2.135
5.42
3 years 1.73
Extreme 1.726
7.85
5 years 1.73
Extreme 1.726
29.7
10 years 1.73
Extreme 1.726
29.7
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 28/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 19/12/2023
Director/Board Member 75 06/03/2013
Chairman 65 19/12/2023
Date Insider Type Main position Quantity % Market Cap.
01-26Sell

Chief Technology Officer

11,800 0.0069%
01-25Sell

Chief Financial Officer

11,800 0.0069%
01-18Sell

Chief Operating Officer

6,206 0.0036%
Change 5-day change 1-year change 3-year change Capi.($)
+3.25%-2.47%-15.96%-63.47% 502M
-0.35%+0.97%-15.96%-12.73% 43.03B
+3.11%+3.11%+274.29%+507.94% 32.71B
+0.22%-1.08%+14.03%-14.37% 30.29B
+1.62%-2.08%-4.36%+24.05% 29.4B
+4.09%+0.93%+10.83%+18.78% 25.08B
-1.63%+2.88%+53.73%+114.36% 13.35B
+1.14%+3.62% - - 13.54B
-0.40%-1.29%+6.06%+7.59% 12.97B
-0.74%-1.62%+105.71%+76.01% 12.11B
Average +1.03%+1.06%+47.60%+73.13% 21.3B
Weighted average by Cap. +1.06%+1.47%+54.77%+96.90%

Financials

2026 *2027 *
Net sales 152M 176M 140M 131M 245M 16.71B 249M 1.65B 644M 8.13B 660M 646M 28.16B 294M 340M 271M 254M 475M 32.36B 483M 3.2B 1.25B 15.75B 1.28B 1.25B 54.54B
Net income -66.01M -76.43M -60.83M -56.94M -107M -7.26B -108M -718M -280M -3.54B -287M -281M -12.24B 70.5M 81.63M 64.97M 60.81M 114M 7.76B 116M 767M 299M 3.78B 306M 300M 13.08B
Net Debt 128M 148M 118M 110M 207M 14.09B 210M 1.39B 543M 6.86B 556M 544M 23.74B 60.02M 69.49M 55.31M 51.77M 97.02M 6.6B 98.52M 653M 255M 3.21B 261M 255M 11.13B
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
674
Date Price Change Volume
12/06/26 2.286 +3.25% 352,774
11/06/26 2.214 -1.42% 583,232
10/06/26 2.246 -1.32% 460,530
09/06/26 2.276 -1.56% 332,827
08/06/26 2.312 -1.37% 509,268
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.286EUR
Average target price
5.233EUR
Spread / Average Target
+128.93%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!